Allurion Technologies downgraded by Chardan Capital Markets
$ALUR
Medical/Dental Instruments
Health Care
Chardan Capital Markets downgraded Allurion Technologies from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2024 | Buy → Neutral | Chardan Capital Markets | |
| 10/2/2024 | $2.00 | Buy | TD Cowen |
| 9/6/2024 | $2.00 | Buy | ROTH MKM |
| 2/9/2024 | $5.00 | Buy | Jefferies |
4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)
4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)
4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)
SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)
SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)
SC 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)
Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the third quarter ended September 30, 2024 and provided a business update. Recent Company Highlights Revenue of $5.4 million, which includes a reduction of $1.2 million for product recalled from France during the third quarter AI product revenue in the third quarter from the Virtual Care Suite (VCS) grew by 82% versus prior year as first patients in the United States treated with GLP-1s were on-boarded Last patient in AUDACITY FDA clinical trial successfully exited, putting top-line readout on track for the end of the year Work
19,428 patients treated with the Allurion Program across 72 countries lost an average of 12.2% of total body weight Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the presentation of two abstracts at Obesity Week 2024, the annual meeting of The Obesity Society. The first abstract comprises outcomes data from Allurion's largest real-world cohort on record. The data, gathered from 19,428 patients across 72 countries treated between 2018 and 2023 with the Allurion Program with results tracked digitally through the Allurion Virtual Care Suite, reveals consistent and significant weight loss outcomes with an average weight reduction of 12.2% at f
Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay of the conf
Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the third quarter ended September 30, 2024 and provided a business update. Recent Company Highlights Revenue of $5.4 million, which includes a reduction of $1.2 million for product recalled from France during the third quarter AI product revenue in the third quarter from the Virtual Care Suite (VCS) grew by 82% versus prior year as first patients in the United States treated with GLP-1s were on-boarded Last patient in AUDACITY FDA clinical trial successfully exited, putting top-line readout on track for the end of the year Work
Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay of the conf
Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced that it will report financial results for the second quarter 2024 on Tuesday, August 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay of the confe
Chardan Capital Markets downgraded Allurion Technologies from Buy to Neutral
TD Cowen initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00
ROTH MKM initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00
Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "I believe having Keith as a sounding board as we leverage the opportunities created by GLP-1s will be a competitive advantage." Omar Ishrak, Al
Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company's international commercial sales and operations functions. "We are thrilled to welcome Adrian to Allurion and add his expertise to our leadership team as we advance the company toward profitability," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "Adrian joins us at an extremely important time – where the obesity market is expandi
Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working closely with the Board and Executive Leadership Team. Ojas will provide strategic and execution-focused guidance aimed to help the company achieve major milestones and scale sustainably. With a 25-year track record in the health
424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)
Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced the pricing of an underwritten public offering of 14,406,508 shares of its common stock, par value $0.0001 per share (the "Shares"), and warrants to purchase 14,406,508 Shares (the "Warrants" and, together with the Shares, the "Securities") at a public offering price of $1.20 per share, for total gross proceeds of $17.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.Jefferies and TD Cowen are acting as joint book-running managers and representatives of the underwriters for the offering. Roth Capital